Table 1 Inclusion and exclusion criteria used when screening articles first by title and abstract and then by full text. Papers were included if they were primary studies of any study design. The population being studied was infants born early pre-term up to term. The studies were investigating monoclonal antibody prophylaxis compared with no prophylaxis or placebo, on the outcome of recurrent wheeze or asthma. No studies investigating a population of infants with congenital defects were included, and no other RSV prophylaxis or treatment apart from monoclonal antibody was considered
Include | Exclude |
|---|---|
All study designs | Reviews |
Primary studies, including peer-reviewed and grey literature | Letters |
All ethnicities | Not about prophylaxis |
Population: Infants born early pre-term up to term, followed up for 1–10 years | Population: Infants with congenital heart defects or lung conditions such as bronchopulmonary dysplasia |
Intervention: RSV prophylaxis with monoclonal antibody | Any other interventions such as RSV Prophylaxis or treatment with RSV-specific immune globulins, steroids, vaccines, macrolides etc. |
Comparison: No prophylaxis or placebo | Comparison: Different dosing regimen of monoclonal antibody |
Outcome: Recurrent wheeze or asthma development | Bronchiolitis caused by other allergens or viruses such as rhinovirus |